

# 1           **RT-LAMP has high accuracy for detecting SARS-CoV-2 in saliva and** 2           **naso/oropharyngeal swabs from asymptomatic and symptomatic individuals**

3           **Short title:** RT-LAMP for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs

4           †Stephen P. Kidd<sup>1,2</sup>, †Daniel Burns<sup>1,3</sup>, Bryony Armson<sup>1,2,4</sup>, Andrew D. Beggs<sup>5</sup>, Emma L. A. Howson<sup>6</sup>,  
5           Anthony Williams<sup>7</sup>, Gemma Snell<sup>7</sup>, Emma L. Wise<sup>1,8</sup>, Alice Goring<sup>1</sup>, Zoe Vincent-Mistiaen<sup>9</sup>, Seden  
6           Grippon<sup>1</sup>, Jason Sawyer<sup>10</sup>, Claire Cassar<sup>10</sup>, David Cross<sup>10</sup>, Tom Lewis<sup>10</sup>, Scott M. Reid<sup>10</sup>, Samantha  
7           Rivers<sup>10</sup>, Joe James<sup>10</sup>, Paul Skinner<sup>10</sup>, Ashley Banyard<sup>10</sup>, Kerrie Davies<sup>11</sup>, Anetta Ptasinska<sup>5</sup>, Celina  
8           Whalley<sup>5</sup>, Jack Ferguson<sup>5</sup>, Claire Bryer<sup>5</sup>, Charlie Poxon<sup>5</sup>, Andrew Bosworth<sup>5</sup>, Michael Kidd<sup>5,12</sup>, Alex  
9           Richter<sup>13</sup>, Jane Burton<sup>14</sup>, Hannah Love<sup>14</sup>, Sarah Fouch<sup>1</sup>, Claire Tillyer<sup>1</sup>, Amy Sowood<sup>1</sup>, Helen Patrick<sup>1</sup>,  
10           Nathan Moore<sup>1</sup>, Michael Andreou<sup>15</sup>, Nick Morant<sup>16</sup>, Rebecca Houghton<sup>1</sup>, Joe Parker<sup>17</sup>, Joanne Slater-  
11           Jefferies<sup>17</sup>, Ian Brown<sup>10</sup>, Cosima Gretton<sup>2</sup>, Zandra Deans<sup>2</sup>, Deborah Porter<sup>2</sup>, Nicholas J. Cortes<sup>1,9</sup>, Angela  
12           Douglas<sup>2</sup>, Sue L. Hill<sup>2</sup>, \*Keith M. Godfrey<sup>18,19</sup>, \*Veronica L. Fowler<sup>1,2</sup>

13

14           <sup>1</sup>Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and North Hants  
15           Hospital, Basingstoke, UK

16           <sup>2</sup>NHS Test and Trace Programme, Department of Health and Social Care, UK

17           <sup>3</sup>School of Electronics and Computer Science, University of Southampton, UK

18           <sup>4</sup>vHive, School of Veterinary Medicine, University of Surrey, Guildford, UK

19           <sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

20           <sup>6</sup>The Pirbright Institute, Ash Road, Pirbright, Woking, UK

21           <sup>7</sup>University of Southampton & Division of Specialist Medicine, University Hospital Southampton, UK

22           <sup>8</sup>School of Biosciences and Medicine, University of Surrey, Guildford, UK

23           <sup>9</sup>Gibraltar Health Authority, Gibraltar, UK

24           <sup>10</sup>Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

25           <sup>11</sup>Leeds Teaching Hospitals NHS Trust and University of Leeds, UK

26           <sup>12</sup>Public Health West Midlands Laboratory, Birmingham, UK

27           <sup>13</sup>Institute of Immunology and Immunotherapy, University of Birmingham, UK

28           <sup>14</sup>High Containment Microbiology, National Infection Service, Public Health England, Porton Down, UK

29           <sup>15</sup>OptiSense Limited, Horsham, West Sussex, UK

30           <sup>16</sup>GeneSys Biotech Limited, Camberley, Surrey, UK

31           <sup>17</sup>National Biofilms Innovation Centre, University of Southampton, UK

32           <sup>18</sup>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital, UK

33           <sup>19</sup>MRC Lifecourse Epidemiology Centre, University of Southampton, UK

34

35           †Denotes co-first authorship; †Senior author; \*Corresponding author: - [kmg@soton.ac.uk](mailto:kmg@soton.ac.uk);

36

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

37 **Abstract**

38 Previous studies have described RT-LAMP methodology for the rapid detection of SARS-CoV-2 in  
39 nasopharyngeal/oropharyngeal swab and saliva samples. Here we describe the validation of an  
40 improved sample preparation method for extraction free Direct RT-LAMP and define the clinical  
41 performance of four different RT-LAMP assay formats for detection of SARS-CoV-2 within a large-scale  
42 multisite clinical evaluation.

43 We describe Direct RT-LAMP on 559 swabs and 86,760 saliva samples and RNA RT-LAMP on extracted  
44 RNA from 12,619 swabs and 12,521 saliva samples collected from asymptomatic and symptomatic  
45 individuals across multiple healthcare and community settings.

46 For Direct RT-LAMP, we found a diagnostic sensitivity (DSe) of 70.35% (95% CI 63.48-76.60%) on swabs  
47 and 84.62% (79.50-88.88%) on saliva, with diagnostic specificity (DSp) of 100% (98.98-100.00%) on  
48 swabs and 100% (99.72-100.00%) on saliva when compared to RT-qPCR. Analysing samples with RT-  
49 qPCR ORF1ab  $C_T$  values of  $\leq 25$  and  $\leq 33$  (high and medium-high viral copy number, respectively), we  
50 found DSe of 100% (96.34-100%) and 77.78% (70.99-83.62%) for swabs, and 99.01% (94.61-99.97%)  
51 and 87.32% (80.71-92.31%) for saliva. For RNA RT-LAMP DSe and DSp were 95.98% (92.74-98.06%)  
52 and 99.99% (99.95-100%) for swabs, and 80.65% (73.54-86.54%) and 99.99% (99.95-100%) for saliva,  
53 respectively.

54 The findings from these evaluations demonstrate that RT-LAMP testing of swabs and saliva is  
55 applicable to a variety of different use-cases, including frequent, interval-based testing of saliva from  
56 asymptomatic individuals via Direct RT-LAMP that may otherwise be missed using symptomatic testing  
57 alone.

58

59

60

61 **Author Summary**

62 Rapid diagnostic testing at scale to identify and isolate symptomatic and asymptomatic individuals  
63 potentially transmitting infectious SARS-CoV-2 is an essential part of the response to the COVID-19  
64 pandemic. RT-LAMP on both extracted RNA and directly on crude samples potentially provides faster  
65 turnaround times than reverse-transcriptase quantitative real-time PCR testing, with a higher  
66 sensitivity and specificity than antigen lateral flow devices. Increasing evidence points to potential  
67 benefits of SARS-CoV-2 testing using saliva rather than nasopharyngeal/oropharyngeal swabs, leading  
68 us to undertake a multi-site evaluation of an improved simple sample preparation method for Direct  
69 SARS-CoV-2 RT-LAMP. Our study demonstrated that the RNA RT-LAMP assay has high sensitivity and  
70 specificity, providing a rapid alternative to RT-qPCR testing with a reliance on differing reagents and  
71 equipment. The simple SARS-CoV-2 Direct RT-LAMP preparation method also demonstrated high  
72 sensitivity and specificity for detecting SARS-CoV-2 in saliva and naso/oropharyngeal swabs from  
73 asymptomatic and symptomatic individuals, notably in saliva samples from which the individual would  
74 likely be considered infectious. The findings highlight the usefulness of saliva as a simple to collect,  
75 non-invasive, sample type, potentially applicable for interval-based testing of asymptomatic  
76 individuals.

77

## 78 Introduction

79 Rapid diagnostic testing to identify and isolate symptomatic and asymptomatic individuals  
80 potentially transmitting infectious viral pathogens is an essential requirement of any pandemic  
81 response. The novel *betacoronavirus*, SARS-CoV-2, initially identified after an outbreak of viral  
82 pneumonia in Wuhan, China in December 2019(1), has rapidly spread throughout the world, causing  
83 over 141 million confirmed cases and over 3.1 million deaths(2), (April, 2021).

84 Conventional diagnostics for SARS-CoV-2 consist of RNA enrichment followed by reverse-  
85 transcriptase quantitative real-time PCR (RT-qPCR) against one or more viral gene targets(3).  
86 However, this methodology requires sample inactivation, RNA extraction and RT-qPCR thermal  
87 cycling, meaning that the time from sample-to-result can often be several hours, and requires  
88 centralised equipment and personnel trained in Good Laboratory Practice to perform testing.

89 We have previously shown the utility of reverse-transcriptase loop mediated isothermal  
90 amplification (RT-LAMP) for the detection of SARS-CoV-2 both from extracted RNA (RNA RT-LAMP)  
91 and directly from nasopharyngeal/oropharyngeal swabs (Direct RT-LAMP)(4). RT-LAMP utilises a  
92 rapid and stable DNA polymerase that amplifies target nucleic acids at a constant temperature. This  
93 removes the requirement for conventional thermal cycling allowing RT-LAMP reactions to be  
94 performed in shorter reaction times using less sophisticated platforms.

95 In a study of 196 clinical samples(4), testing of RNA extracted from nasopharyngeal/oropharyngeal  
96 swabs collected into viral transport media (VTM) using RNA RT-LAMP demonstrated a diagnostic  
97 sensitivity (DSe) of 97% and a diagnostic specificity (DSp) of 99% in comparison to RT-qPCR of the  
98 ORF1ab region of SARS-CoV-2. For Direct RT-LAMP on crude swab samples, the DSe and DSp were  
99 67% and 97%, respectively. When a cycle threshold ( $C_T$ ) cut-off for RT-qPCR of < 25 was considered,  
100 reflecting the increased likelihood of detecting viral RNA from active viral replication, the DSe of  
101 Direct RT-LAMP increased to 100% (4).

102 However, the collection of a swab sample is invasive and during the time of the pandemic there have  
103 been considerable shortages in swab supplies. Exploring the use of alternative sample types that are  
104 both easy to collect and more of a comfortable from a sampling perspective is desirable particularly  
105 when repeat sampling is performed. Saliva presents an ideal bio-fluid that fulfils both these  
106 objectives and previous studies have shown that SARS-CoV-2 is readily detectable in such a sample  
107 type(5–10). To improve the diagnostic sensitivity of previously described saliva Direct RT-LAMP(4),  
108 optimisation of saliva preparation for the detection of SARS-CoV-2 was undertaken utilising a cohort  
109 of 3100 saliva samples from an asymptomatic population(11) of healthcare workers; where saliva  
110 was diluted 1:1 in Mucolyse™, followed by a 1 in 10 dilution in 10% (w/v) Chelex® 100 Resin ending  
111 with a 98°C heat step prior to RT-LAMP which resulted in optimal sensitivity and specificity.

112 Despite the benefits of this optimisation, the protocol added additional steps and reagents which  
113 increased chance for user error and made the automation of the process more challenging. We  
114 therefore aimed to investigate a simpler process using a novel reagent, RapiLyze (OptiGene Ltd),  
115 which is a sample dilution buffer, followed by a two-minute heat-step. This novel sample  
116 preparation method was evaluated in combination with Direct RT-LAMP using samples collected  
117 from symptomatic National Health Service (NHS) patients and symptomatic and asymptomatic  
118 healthcare staff.

119

120

## 121 **Results**

### 122 **RNA RT-LAMP**

123 VTM from 12,619 naso/oropharyngeal swabs were assayed. 265 swab samples were from known  
124 symptomatic individuals and 2073 swab samples were from known asymptomatic individuals. The  
125 clinical status of the remaining samples (n= 10,281) was unknown.

126 12,521 neat saliva samples were assayed, none of which were from known symptomatic individuals.  
127 12,365 of these samples were from known asymptomatic individuals. The clinical status of the  
128 remaining saliva samples (n= 156) was unknown.

### 129 **Direct RT-LAMP**

130 VTM from 559 naso/oropharyngeal swabs were assayed. 170 swab samples were from known  
131 symptomatic individuals and 310 samples were from known asymptomatic individuals and the  
132 clinical status of the remaining swab samples (n= 79) was unknown.

133 86,760 neat saliva samples were assayed. 93 samples were from known symptomatic individuals and  
134 86,593 samples were from known asymptomatic individuals. The clinical status of the remaining  
135 samples (n= 74) was unknown. In addition, 10 separate longitudinal daily saliva samples were  
136 provided from one individual as a time course from development of symptoms to three days post  
137 resolution of symptoms.

138

### 139 **RNA RT-LAMP on naso/oropharyngeal swabs**

140 A total of 12,619 swab samples were assayed by RNA RT-LAMP, of which 254 were RT-qPCR positive  
141 and 12,365 were RT-qPCR negative. RNA RT-LAMP detected 244 of the 254 positives (Figure 1a and  
142 Table 1). Only one of the 12,365 samples negative by RT-qPCR was positive by RNA RT-LAMP. 588

143 samples were tested in duplicate and 12,031 were tested as single replicates. Of those samples  
 144 tested in duplicate seven were detected by RNA RT-LAMP in only a single replicate ( $C_T$ s 27.00, 32.66,  
 145 33.14, 33.16, 34.07, 35.05, and 37.20 all of these had received at least one freeze thaw before  
 146 analysis. Overall diagnostic sensitivity (DSe) was 96.06% (95% CI 92.88-98.12) and specificity (DSp)  
 147 99.99% (95% CI 99.95-100.00), which is corrected to DSe 95.98% (95% CI 92.70-97.83) and DSp  
 148 99.99% (95% CI 99.94-100.00) after site meta-analysis Diagnostic sensitivity of samples with a  $C_T \leq 25$   
 149 ( $n = 123$ ) was 100.00% (95% CI 96.76-100.00) and specificity 99.99% (95% CI 99.95-100.00), and of  
 150 samples with a  $C_T \leq 33$  ( $n=180$ ) was 98.65% (95% CI 96.10-99.72) and specificity 99.99% (95% CI  
 151 99.95-100.00).

152 **Table 1.** Diagnostic sensitivity and specificity of RNA RT-LAMP on swabs compared with RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 45</math> Swab</b>	RNA RT-LAMP Pos	244 <sup>†</sup>	1	245	<b>DSe</b>	96.06	92.88-98.12
	RNA RT-LAMP Neg	10	12364	12374	<b>DSp</b>	99.99	99.95-100
	Total	254	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 33</math> Swab</b>	RNA RT-LAMP Pos	219	1	220	<b>DSe</b>	98.95	96.10-99.72
	RNA RT-LAMP Neg	3	12364	12367	<b>DSp</b>	99.9	99.95-100
	Total	222	12365				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 25</math> Swab</b>	RNA RT-LAMP Pos	112	1	113	<b>DSe</b>	100	96.76-100
	RNA RT-LAMP Neg	0	12364	12364	<b>DSp</b>	99.9	99.95-100
	Total	112	12365				

153 <sup>†</sup>Five samples included in this number were positive by RT-qPCR but did not have an associated  $C_T$  value due to being  
 154 assayed on a platform that did not produce a  $C_T$  value. DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

155

156

157 **Direct RT-LAMP on naso/oropharyngeal swabs**

158 559 swab samples were assayed by Direct RT-LAMP of which 199 were RT-qPCR positive and 360  
 159 were RT-qPCR negative. Direct RT-LAMP detected 140 of the 199 samples positive by RT-qPCR  
 160 (Figure 1b and Table 2). 195 samples were tested in duplicate and 364 tested as single replicates.  
 161 Seven of 195 samples tested in duplicate were positive by Direct RT-LAMP in only one replicate ( $C_T$   
 162 27.51, 27.95, 28.15, 28.15, 28.87, 28.92, and 28.95) all these samples had received at least one  
 163 freeze thaw before analysis. Overall diagnostic sensitivity was 70.35% (95% CI 63.48-76.60) and  
 164 specificity 100% (95% CI 98.98-100). After correction by site meta-analysis, the DSe is corrected to  
 165 67.59% (95% CI 53.71-78.94). Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 113) was 100% (95%  
 166 CI 96.34-100) and specificity 100% (95% CI 98.98-100), and of samples with a  $C_T \leq 33$  (n= 182) was  
 167 77.78% (95% CI 70.99-83.62) and specificity 100% (95% CI 98.98-100).

168

169 **Table 2.** Diagnostic sensitivity and specificity of Direct RT-LAMP on swabs compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 45</math> Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b>	70.35	63.48-76.60
	Direct RT-LAMP Neg	59	360	419	<b>DSp</b>	100	98.98-100
	Total	199	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 33</math> Swab</b>	Direct RT-LAMP Pos	140	0	140	<b>DSe</b>	77.78	70.99-83.62
	Direct RT-LAMP Neg	40	360	400	<b>DSp</b>	100	98.98-100
	Total	180	360				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 25</math> Swab</b>	Direct RT-LAMP Pos	99	0	99	<b>DSe</b>	100	96.34-100
	Direct RT-LAMP Neg	0	360	360	<b>DSp</b>	100	98.98-100
	Total	99	360				

170 DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

171

172

173 **RNA RT-LAMP on saliva**

174 Saliva samples numbering 12,521 were assayed by RNA RT-LAMP of which 155 were RT-qPCR  
 175 positive and 12,366 were RT-qPCR negative. RNA RT-LAMP detected 133 of the 155 samples that  
 176 were positive by RT-qPCR (Figure 1c and Table 3). Only one of the 12,366 samples negative by RT-  
 177 qPCR was positive by RNA RT-LAMP. 44 samples were tested in duplicate and 12,477 were tested as  
 178 single replicates. All samples tested in duplicate were positive in both replicates. Overall diagnostic  
 179 sensitivity was 80.65% (95% CI 73.54-86.54) and specificity 99.99% (95% CI 99.95-100), which is  
 180 corrected to DSe 79.05% (95% CI 68.87 – 86.55) and DSp 99.99% (95% CI 99.74-100) after site meta-  
 181 analysis. Diagnostic sensitivity of samples with a  $C_T \leq 25$  (n= 74) was 100% (95% CI 93.73-100) and  
 182 specificity 99.99% (95% CI 99.95-100), and of samples with a  $C_T \leq 33$  (n= 150) was 87.32% (95% CI  
 183 80.71-92.31) and specificity 99.95 (95% CI 99.95-100.00).

184

185

186 **Table 3.** Diagnostic sensitivity and specificity of RNA RT-LAMP on saliva compared to RT-qPCR

		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 45</math> Saliva</b>	RNA RT-LAMP Pos	125	1	126	<b>DSe</b>	80.65	73.54-86.54
	RNA RT-LAMP Neg	30	12365	12395	<b>DSp</b>	99.99	99.95-100
	Total	155	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 33</math> Saliva</b>	RNA RT-LAMP Pos	124	1	125	<b>DSe</b>	87.32	80.71-92.31
	RNA RT-LAMP Neg	18	12365	12383	<b>DSp</b>	99.99	99.95-100
	Total	142	12366				
		RT-qPCR Pos	RT-qPCR Neg	Total		%	95% CI
<b><math>C_T &lt; 25</math> Saliva</b>	RNA RT-LAMP Pos	57	1	58	<b>DSe</b>	100	93.73-100
	RNA RT-LAMP Neg	0	12365	12365	<b>DSp</b>	99.99	99.95-100
	Total	57	12366				

187 DSe: Diagnostic sensitivity. DSp: Diagnostic specificity

188

189

190 **Direct RT-LAMP on saliva**

191 86,760 saliva samples were tested by Direct RT-LAMP of which 247 were RT-qPCR positive and 7,195  
 192 were RT-qPCR negative (79,318 were negative on RT-LAMP but were not tested by RT-qPCR) (Figure  
 193 4d and Table 4). Direct RT-LAMP detected 209 of the 247 samples positive by RT-qPCR. 83 samples  
 194 were tested in duplicate and 86,677 were tested as single replicates. Nine of the 83 samples tested  
 195 in duplicate were negative in one of the duplicates and all these samples had received at least one  
 196 freeze thaw before analysis ( $C_T$  20.27, 21.28, 22.01, 24.42, 25.85, 27.35, 28.52, and 30.37). Overall  
 197 diagnostic sensitivity was 84.62% (95% CI 79.50-88.88) and specificity 100% (95% CI 99.72-100).  
 198 After correction by site meta-analysis, DSe is corrected to 84.24% (95% CI 55.03-95.89). Diagnostic  
 199 specificity was calculated using only the confirmed RT-qPCR negative samples. Diagnostic sensitivity  
 200 of samples with a  $C_T \leq 25$  (n= 126) was 99.01% (95% CI 94.61-99.97) and specificity 100.00% (95% CI  
 201 99.72-100), and of samples with a  $C_T \leq 33$  (n= 237) was 87.61% (95% CI 82.69-91.54) and specificity  
 202 100% (95% CI 99.72-100).

203 **Table 4.** Diagnostic sensitivity and specificity of Direct RT-LAMP on saliva compared to RT-qPCR.


		RT-qPCR Pos	RT-qPCR Neg	Total	%	95% CI
<b><math>C_T &lt; 45</math> Saliva</b>	Direct RT-LAMP Pos	209	0	209	<b>DSe</b> 84.62	79.50-88.88
	Direct RT-LAMP Neg	38	7195*	7233	<b>DSp</b> 100.00	99.95-100.00
	Total	247	7195			
<b><math>C_T &lt; 33</math> Saliva</b>	Direct RT-LAMP Pos	205	0	205	<b>DSe</b> 87.61	82.69-91.54
	Direct RT-LAMP Neg	29	7195*	7224	<b>DSp</b> 100.0	99.95-100.00
	Total	234	7195			
<b><math>C_T &lt; 25</math> Saliva</b>	Direct RT-LAMP Pos	100	0	100	<b>DSe</b> 99.01	94.61-99.97
	Direct RT-LAMP Neg	1	7195*	7196	<b>DSp</b> 100.0	99.95-100.00
	Total	101	7195			

204 \*85,177 samples were negative on RT-LAMP but only 7,196 were confirmed negative by RT-qPCR. Only those  
 205 which were confirmed negative by RT-qPCR were included in the calculations.

206

207 Relationship between cycle threshold ( $C_T$ ) value and time to positivity ( $T_p$ )

208



209

210

211 **Figure 1a-d:** RT-LAMP on swabs (a: RNA RT-LAMP; b: Direct RT-LAMP) and saliva (c: RNA RT-LAMP; d: Direct  
212 RT-LAMP). Time to positivity [ $T_p$ ] in minutes plotted against RT-qPCR Cycle Threshold [ $C_T$ ]. Samples which were  
213 negative by RT-qPCR are not shown. Samples which were negative by RT-LAMP are shown with 0 time to  
214 positivity. Results of linear ordinary least squared regression are shown for samples which were RT-LAMP  
215 positive with corresponding 95% confidence interval.

216

217 The relationship between  $C_T$  value and  $T_p$  was explored with the results shown in Figure 1. Whilst  
218 there is a weak linear relationship between  $C_T$  value and  $T_p$  across all methods and sample types, a  
219 stronger linear relationship was observed in swab samples with  $R^2 = 0.431$  for RNA RT-LAMP and  
220  $R^2 = 0.462$  for Direct RT-LAMP. There was a notably weaker linear relationship in saliva samples  
221  $R^2 = 0.201$  for RNA RT-LAMP and  $R^2 = 0.204$  for Direct RT-LAMP. For RNA RT-LAMP, there was a  
222 notable increase in  $T_p$  variance,  $\sigma_{T_p}^2$ , after  $C_T = 20$  across both sample types. On saliva samples,  
223  $\sigma_{T_p}^2 = 0.81$  for  $C_T \leq 20$ , and  $\sigma_{T_p}^2 = 20.41$  for  $C_T > 20$ ; on swabs samples,  $\sigma_{T_p}^2 = 1.96$  and  $C_T \leq 20$ , and  
224  $\sigma_{T_p}^2 = 15.72$  for  $C_T > 20$

225

## 226 Individual time course

227 In the time course experiment SARS-CoV-2 RNA was detected from day 5 (at the onset of symptoms)  
228 up to day 12 post suspected initial exposure using Direct RT-LAMP and up to day 13 by RNA RT-  
229 LAMP, encompassing the full six days where symptoms were recorded (Supplementary Information).

230

## 231 SARS-CoV-2 viral culture of clinical samples across a $C_T$ range

232 Although not a large sample size; a negative result via Direct RT-LAMP does seem indicate the  
233 presence of culturable virus is less probable and recoverable virus  $C_T > 25$  for RDRP/ORF1ab target is  
234 less likely. The sensitivity of the viral culture assay is presented in Supplementary data 2 of 1 pfu/ml.

235

236

237

238

239


Sample	Direct RT-LAMP	RNA RT-LAMP	C <sub>T</sub> values			cpe	Decrease in C <sub>T</sub> from P0 D0 to P0 D7	C <sub>T</sub> decrease D0 to D7	
			Genesig RDRP gene	VIASURE	SARS-CoV E gene Sarbeco assay			P1	P2
				ORF1ab					
1	POS	POS	19.9	18.7	17.8	+ P2¶	+	n/a	n/a
2	POS	POS	21.3	19.9	19.0	+	+	n/a	n/a
3	POS	POS	21.6	19.1	18.5	+	+	n/a	n/a
4	POS	POS	22.6	20.8	19.8	+	+	n/a	n/a
5	POS	POS	22.9	21.6	21.0	+	+	n/a	n/a
6	POS	POS	23.7	20.6	20.6	+	+	n/a	n/a
7	NEG*	POS	24.3	21.4	20.4	+	+	n/a	n/a
8	NEG*	POS	25.3	22.0	21.3	No cpe	n/a	n/a	n/a
9	NEG*	POS	26.0	23.7	23.0	+	+	n/a	n/a
10	NEG*	NEG	36.1	31.5	32.7	No cpe	n/a	n/a	n/a
11	NEG	POS	-			No cpe	No	No	No
12	NEG	POS	39.2			No cpe	No	No	No
13	NEG	POS	35.2			No cpe	No	No	No
14	NEG	NEG	34.6			No cpe	No	No	No
15	NEG	POS	35.4			No cpe	No	No	No
16	NEG	POS	36.2			No cpe	No	No	No
17	POS	POS	35.8			No cpe	No	No	No
18	POS	POS	34.5			No cpe	No	No	No
19	NEG	POS	35.1			No cpe	No	No	No
20	POS	POS	30.0			No cpe	No	No	No
21	POS	POS	32.3			No cpe	No	No	No
22	NEG	POS	34.6			No cpe	No	No	No
23	POS	POS	31.3			No cpe	No	No	No
24	NEG	POS	30.3			No cpe	No	No	No
25	NEG	POS	30.0			No cpe	No	No	No
26	NEG	POS	31.5			No cpe	No	No	No
27	NEG	POS	30.7			+	No	No	No
28	POS	POS	29.9			No cpe	No	No	No
29	POS	POS	29.4			No cpe	No	No	No
30	NEG* <sup>2</sup>	POS	28.2			+	Yes	No	No

240 Table 5: Viral culture of positive VTM from oro/pharyngeal swabs and assay results. Original sample result was  
 241 generated from Genesig RDRP assay at time of diagnosis. \*Previously un-optimised method without lysis  
 242 buffer. \*2 – precipitate observed in lysis mix.

243


244

245 Performance of RT-LAMP across viral load groups



246

247



248

249 **Figure 2:** Performance of the RNA RT-LAMP and Direct RT-LAMP assays on both saliva and swab samples  
 250 according to viral load groupings.

251 The sensitivity of the RNA and Direct RT-LAMP assays across viral load groups is shown in Figure 2.  
252 For RNA RT-LAMP, samples which were positive by RT-qPCR containing  $>10^5$  copies/ml were  
253 consistently identified as positive with no samples returning a negative result. Below this copy  
254 number, sensitivity is reduced for both saliva and swab samples, reaching ~60% in swab samples  
255 exclusively with viral loads  $<10^3$  copies/ml, and an approximately linear drop in sensitivity from 100%  
256 to 0% between viral loads of  $10^5$  and  $10^3$  copies/ml respectively in saliva samples. For Direct RT-  
257 LAMP, all but one saliva sample were detected above  $10^6$  copies/ml. On swab samples, sensitivity is  
258 reduced on samples containing below  $<10^5$  copies/ml, dropping from 85% at viral loads of  $10^5$ – $10^6$   
259 copies/ml, to 30% in the  $10^4$ – $10^5$  range. On saliva samples, sensitivity is reduced in the  $10^4$ – $10^5$  range  
260 to a sensitivity of 80% but then reduces further within the  $10^3$ – $10^4$  range, to 30%.

261

262

263

264

265

266

267

268


269

270

271


272

273 Site meta-analysis



274


### Direct RT-LAMP Swabs




275

276

### RNA RT-LAMP Saliva



### Direct RT-LAMP Saliva



279 **Figure 3:** Forest plots for each method and sample type showing site heterogeneity in sensitivity and specificity,  
280 with overall estimates and the resulting expected sensitivity and specificity retrieved from each respective  
281 bivariate random effects model.

282

283 Site-level confusion matrices, sensitivity, and specificity per method and sample type in Figure 3.

284 Heterogeneity between sites for the specificity was minimal for all combinations of method and

285 sample type, with the random effects model matching the overall aggregated sample calculation. For

286 sensitivity, heterogeneity was minimal between sites for RNA RT-LAMP. However, for Direct RT-

287 LAMP, sensitivity showed significant overall heterogeneity (bivariate model variance:  $\sigma_{se}^2 = 1.817$

288 on saliva samples;  $\sigma_{se}^2 = 0.228$  on swab samples). Between-site variations in the viral load of the

289 samples tested contributed a minority of the heterogeneity, but sensitivity was consistently high in

290 samples with higher viral loads (i.e.,  $>10^6$  copies/ml, as shown in Figure 2), while being more

291 heterogeneous between sites in samples with lower viral loads. Sensitivity at lower viral loads was

292 highest in the sites with the most established testing programmes.

293

## 294 Discussion

295 Testing of human populations for SARS-CoV-2 nucleic acid has been hampered by both logistical  
296 (e.g., swab availability) and physical (e.g., discomfort from repeat swab testing) constraints. The aim  
297 of this study was to evaluate an optimised sample preparation method, building upon previously  
298 published methods for the extraction-free detection of SARS-CoV-2 by RT-LAMP primarily from  
299 saliva(4,11). Collection of saliva is non-invasive and does not require a trained individual or specialist  
300 consumables for collection of a quality sample. Utilising a non-invasive sampling method should  
301 open testing to more individuals who dislike or are unable to tolerate having a  
302 nasopharyngeal/oropharyngeal swab taken. The salivary glands are reported to be early targets of  
303 SARS-CoV-2 infection(16)(17), and studies have demonstrated the detection of high viral loads of  
304 SARS-CoV-2 from saliva, similar to those observed from nasopharyngeal/oropharyngeal  
305 swabs(5,7,18)(19). Additionally, several studies have demonstrated that SARS-CoV-2 viral RNA could  
306 be detected from saliva for a similar duration post onset of clinical signs when compared to  
307 combined naso/oropharyngeal swabs(20–22), highlighting saliva as a valuable tool for SARS-CoV-2  
308 detection.

309 Direct detection negates the requirement for RNA extraction(23)(24), for which there has previously  
310 been competition for reagents and often requires expensive extraction equipment including liquid  
311 handling automation. This extraction-free method decreases turnaround time from sample  
312 collection to result. The Direct RT-LAMP method is straight forward and rapid, allowing the test to be  
313 performed in a wide range of settings, including near-patient hospital laboratories and pop-up or  
314 mobile laboratories. However, previously evaluated extraction-free sample preparation methods  
315 using RT-LAMP from saliva samples have demonstrated reduced sensitivity(4,11), likely due to the  
316 inhibitory factors found within saliva that may affect molecular tests such as RT-LAMP and RT-  
317 qPCR(25,26). The simple sample preparation method evaluated in the study aimed to improve upon  
318 these methods by utilising the addition of a novel proprietary reagent, RapiLyze<sup>®</sup>, designed to

319 neutralize common sample inhibitors. A subsequent heat step of 98°C for two minutes prior to  
320 addition to the RT-LAMP master mix renders SARS-CoV-2 inactive as confirmed by infectivity analysis  
321 using live virus inactivation studies (See supplementary 2). Downstream steps are then able to  
322 proceed outside of traditional containment level laboratory settings broadening its clinical utility.

323 Our study utilised high numbers of combined naso/oropharyngeal swabs (n= 559) and saliva samples  
324 (n = 86,760) for the evaluation of this novel sample preparation method in combination with the  
325 Direct RT-LAMP assay. RNA RT-LAMP was also performed on >25,000 samples for comparison,  
326 providing updated values for the performance of the assay reported previously(4,11,27). Correlation  
327 between  $C_T$  value and sample viral copy number has been demonstrated within this and other  
328 studies, with lower  $C_T$  values  $C_T$  (< 25 and < 33) indicating a higher probability that the sample  
329 contains recoverable active virus, and consequently the likelihood that the individual may be  
330 infectious to others<sup>4,25</sup>(28–31). As a result, the RNA and Direct RT-LAMP assays were compared with  
331 RT-qPCR results in groups with three different  $C_T$  cut-off values: <45, <33 and <25. This was  
332 completed so that the performance of the assays in different clinical scenarios (use case) could be  
333 determined: (i)  $C_T$ <45: does the RT-LAMP assay (either RNA or Direct) compare with RT-qPCR for all  
334 reportable  $C_T$  values?; (ii)  $C_T$ <33: can the RT-LAMP assay detect those individuals that have a  
335 medium-high levels of viral RNA in their specimens, with an ORF1ab target being analogous with  
336 viral copy number because it is exclusively a genomic target(14); and (iii)  $C_T$ <25: can the RT-LAMP  
337 assay detect those individuals that have a high level of viral RNA in their specimens?

338 In our study, diagnostic sensitivity for RNA RT-LAMP on swab and saliva samples was improved when  
339 compared to a previous report utilising this method (Fowler *et al.*, 2020), with values of >96% and  
340 >80%, respectively when considering all  $C_T$  values, and 100% for both sample types when considering  
341  $C_T$ <25 with these samples having a high probability of containing replicating virus for over 24,000  
342 samples tested. Direct RT-LAMP sensitivity on swab samples was also improved from the previous  
343 method with 100% sensitivity for  $C_T$ <25, 77.78% for  $C_T$ <33 and 70.35% for  $C_T$ <45 across 559 samples

344 used for this evaluation. In contrast, sensitivity for Direct RT-LAMP on saliva was in general higher  
345 than that determined for swabs ( $C_T < 33 = 87.61\%$ ,  $C_T < 45 = 84.62\%$ ), apart from the group with  $C_T$   
346 values below  $< 25$ , which had a reported sensitivity of 99.01%. These results support previous reports  
347 which demonstrate comparable performance when comparing paired swabs and saliva  
348 samples(32,33), and that one sample type is not superior to the other. Interestingly, the diagnostic  
349 sensitivity for RNA and Direct RT-LAMP for saliva samples was almost equivalent (80.65% and  
350 84.62%, respectively) suggesting that RNA extraction may not even be required when performing  
351 testing on saliva samples.

352 Previous studies have described the importance of identifying asymptomatic individuals, particularly  
353 those with high viral loads(34–37). The ability of the Direct RT-LAMP assay to reliably detect  
354 individuals with medium-high viral loads in a simple to collect, non-invasive sampling process  
355 highlights the suitability of this assay for both symptomatic and asymptomatic population screening.  
356 This is particularly important in healthcare and care home staff where the use of asymptomatic  
357 COVID-19 screening would reduce the risk of onward transmission of SARS-CoV-2, consequently  
358 maintaining NHS capacity and Social Care capacity and more importantly, reducing the risk to  
359 vulnerable individuals present within those environments(27).

360 It is important to note that when designing surveillance strategies for asymptomatic infection testing  
361 as an intervention to reduce transmission, frequency of testing and result turnaround time may be  
362 considered more significant than diagnostic sensitivity(38). ‘Gold standard’ tests with high sensitivity  
363 such as RT-qPCR generally need to be performed in centralised testing facilities, often resulting in  
364 increased reporting times, leading to a less effective control of viral transmission(38). In contrast,  
365 point of care tests such as Lateral flow tests (LFT)(39) or those requiring only a basic/mobile  
366 laboratory set-up such as Direct RT-LAMP, which have the ability to produce rapid results, can be  
367 performed frequently e.g., daily or multiple times per week. Consequently, the likelihood of  
368 sampling an individual when their viral load is highest as seen in the early, often pre-symptomatic

369 stages of infection increases, maximising the probability of rapidly detecting infectious cases,  
370 allowing prompt isolation. In this use case sampling and testing frequency using a rapid assay with  
371 suitable accuracy in detection of medium-high viral loads, but not necessarily optimal sensitivity over  
372 the whole range including low to very low viral loads, is desirable or necessary(38,40). Frequent on-  
373 site testing of asymptomatic NHS healthcare workers using Direct RT-LAMP has been successfully  
374 implemented in the pilot study described here; and continues to be utilised. Direct-RT-LAMP has also  
375 been used in a mass community based pilot in school and higher education settings(27), to identify  
376 those individuals who may have been missed when surveillance relies only on symptomatic  
377 individuals coming forward for testing. With the use of mobile or pop-up laboratories, Direct RT-  
378 LAMP could also be used for risk-based mass testing, for example, targeting specific geographical  
379 areas or vulnerable groups. The potential also exists for lyophilisation of the Direct RT-LAMP  
380 reagents reported in other studies(41,42), which would minimise the necessity for trained personnel  
381 by reducing pipetting steps and the requirement for a cold chain, allowing greater capacity of the  
382 assay in multi-use case scenarios including point-of-care and in low- and middle-income countries  
383 (LMICs).

384 Several experiments typical of a diagnostic performance evaluation were not performed as part of  
385 this study, as they had been performed and reported previously. This included both analytical  
386 specificity, which when tested against a panel of respiratory pathogens causing indistinguishable  
387 clinical signs to COVID-19, demonstrated a high level of analytical specificity (100% in this case)(4)  
388 and analytical sensitivity of the Direct RT-LAMP, which is reported to detect 1000 cp/ml(4,27,32).  
389 Additionally, the RNA and Direct RT-LAMP assays evaluated as part of this study have been shown to  
390 reliably detect the emerging variants of concern (VOC) including the B.1.1.7 alpha variant, the  
391 501Y.V2 beta variant, the P1 gamma variant and the new rapidly spreading B.1.617.2 delta  
392 variant(43–45). The emergence of further VOC could lead to a criticism of the RT-LAMP assay due its  
393 reliance on a single target, ORF1ab, where mutations in the target region in a sample could lead to  
394 false negatives. For RT-qPCR this has been observed during the current pandemic (46–48) where at

395 least a dual target assay is recommended(49). However, this is less likely to occur for the RT-LAMP  
396 assay used in this pilot evaluation. Firstly, due to the multiple sets of primer pairs utilised, 3 pairs  
397 with two pairs within the target region. This builds in redundancy to mutation not unlike a duplex  
398 RT-qPCR. Secondly, the ORF1ab region is highly conserved and crucial for viral replication and fitness  
399 in SARS-CoV-2. As a result, these regions are well maintained using a proofreading system via the  
400 nsp14 protein(50) resulting in a more stable genome compared to many other RNA viruses.

401 The authors highlight the importance of incorporating an inhibition control into the next iteration of  
402 the RT-LAMP assays. Although, the paired RT-LAMP and RT-qPCR data from this study show a good  
403 correlation and any false negative results were likely due to the analytical sensitivity of the RT-LAMP  
404 assay, not sample driven inhibition. To this end, a control primer set by OptiGene Ltd was evaluated  
405 (PS-0010), targeting the human ribosomal protein LO gene. Preliminary analysis of the inhibition  
406 control primers showed consistent detection across 279 saliva and 381 combined  
407 naso/oropharyngeal swab samples using both RNA and Direct RT-LAMP (Supplement 1).  
408 Incorporation of this inhibition control into the RT-LAMP assays would alleviate a potential limitation  
409 of the current assays and further support quality assurance for use within a clinical diagnostic  
410 setting.

411 This study demonstrated high sensitivity and specificity for a novel sample preparation method used  
412 for SARS-CoV-2 Direct RT-LAMP, particularly in samples from which the individual would likely be  
413 considered infectious, highlighting the usefulness of saliva as a simple to collect, non-invasive sample  
414 type. The highly sensitive RNA RT-LAMP assay provides a rapid alternative with a reliance on  
415 differing reagents and equipment to RT-qPCR testing, thus providing additional diagnostic capacity  
416 and redundancy through diversity. Direct RT-LAMP may complement existing surveillance tools for  
417 SARS-CoV-2 testing including other point-of-care and laboratory-based diagnostics and is applicable  
418 to a variety of clinical scenarios, such as frequent, interval-based testing of asymptomatic individuals  
419 that may be missed when reliance is on symptomatic testing alone. However, care should be taken

420 when considering frequency of testing, messaging around the role and interpretation of  
421 asymptomatic rapid tests, integration of data storage and access, and the challenges faced when  
422 scaling up surveillance to large populations.  
423 The role out of a new testing strategy can often throw up interesting and unexpected experiences.  
424 These collective experiences and lessons learnt from setting up an NHS asymptomatic staff testing  
425 programme using Direct RT-LAMP will be shared in a future publication.

426

## 427 **Methods**

### 428 **Testing sites**

429 The OptiGene Ltd. SARS-CoV-2 RT-LAMP assay was evaluated in nine sites, comprising Basingstoke  
430 and North Hampshire Hospital & Royal Hampshire County Hospital, Hampshire Hospitals NHS  
431 Foundation Trust; University Hospital Southampton; Animal and Plant Health Agency/MRC  
432 Lifecourse Epidemiology Unit (University of Southampton); Public Health Lab Manchester/CMFT;  
433 Leeds Teaching Hospitals NHS Trust; University Hospitals Birmingham NHS Foundation  
434 Trust/Institute of Cancer & Genomic Science University of Birmingham; High Containment  
435 Microbiology, National Infection Service, Public Health England, Porton Down and Public Health  
436 University Laboratory, Gibraltar Health Authority, Gibraltar, UK.

### 437 **Clinical samples**

438 Nasopharyngeal and oropharyngeal swabs were collected from asymptomatic and symptomatic  
439 individuals and placed in viral transport media (VTM).

440 Drooled saliva samples were collected at the start of the day; prior to eating, drinking, teeth  
441 brushing, or using a mouthwash. Saliva was transferred into the specimen pot directly or via a clean  
442 teaspoon, according to a standardised protocol. Samples from UHB deposited saliva straight into the  
443 collection pot.

444 **RNA extraction**

445 RNA was extracted using a range of different methods available at each participating site:

446 *Maxwell® RSC Viral Total Nucleic Acid Purification Kit*

447 In a class 1 microbiological safety cabinet (MSC) within a containment level 3 laboratory, 200 µl of  
448 sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of Genesig® Easy  
449 RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were then  
450 inactivated for 10 minutes at room temperature within the MSC and 10 minutes at 56°C on a heat  
451 block before automated RNA extraction using a Maxwell® RSC48 Instrument (Promega UK Ltd.,  
452 Southampton, UK). RNA was eluted in 50 µl of nuclease-free water (NFW).

453 *MagMAX™CORE Nucleic acid 140 purification kit*

454 10 µl of sample (diluted in 190µl DEPC treated water) was added to 700 µl of prepared lysis solution.  
455 Samples were then inactivated for 10 minutes at room temperature within the safety cabinet before  
456 automated RNA extraction using a Kingfisher Flex (Thermofisher). RNA was eluted in 90 µl of NFW.

457 *Roche FLOW system*

458 RNA extraction was carried out on a MagNA Pure 96 (MP96) extraction robot using the MagNA Pure  
459 96 DNA and Viral Nucleic Acid Small Volume kit (Roche) and the Pathogen 200 universal protocol  
460 v4.0.

461 *Qiagen QIASymphony*

462 RNA extraction was carried out using the QIASymphony Virus/Bacteria Mini Kit (Qiagen) by the  
463 CellFree200 Default IC protocol with a 60 µl extract elution volume.

464

465

466

467 **SARS-CoV-2 Real-Time RT-qPCR**

468 RNA was analysed using a range of different methods available at each site:

469 *CerTest VIASURE SARS-CoV-2 real time qPCR assay*

470 Single step RT-qPCR against the *ORF1ab* region and *N1* gene target of SARS-CoV-2 was carried out  
471 using the CerTest VIASURE SARS-CoV-2 real time PCR kit (CerTest Biotech SL, Zaragoza, Spain)  
472 according to manufacturer's instructions for use (IFU) on either the ThermoFisher QuantStudio 5 or  
473 BioMolecular Systems MIC instruments, using 5 µl of extracted RNA per reaction. RNA extracted  
474 using the Maxwell® RSC Viral Total Nucleic Acid Purification Kit was analysed using this assay.

475 *COVID-19 genesig® Real-Time qPCR assay*

476 Single step RT-qPCR against the *ORF1ab* region of SARS-CoV-2 was carried out using the COVID-19  
477 genesig® Real-Time PCR assay real time PCR assay (Primerdesign Ltd, Chandler's Ford, UK) according  
478 to manufacturer's instructions for use (IFU) on BioMolecular Systems MIC instruments, using 5 µl of  
479 extracted RNA per reaction. RNA extracted using the Maxwell® RSC Viral Total Nucleic Acid  
480 Purification Kit was analysed using this assay.

481 *Corman et al. Real-Time qPCR assay*

482 Single step RT-qPCR against the *E* gene target of SARS-CoV-2 was carried out with the Corman *et al.*  
483 (3) primers using the AgPath-ID™ PCR kit (Thermofisher) according to manufacturer's instructions for  
484 use (IFU) on an Aria qPCR Cycler (Agilent) and results analysed using the Agilent AriaMX 1.5  
485 software, using 5 µl of extracted RNA per reaction. RNA extracted using the MagMAX™CORE Nucleic  
486 acid purification kit were analysed using this assay.

487 RT-qPCR was carried out on an Applied Biosystems Fast 7500 PCR thermocycler in standard run  
488 mode using the SARS-CoV-2 *E* gene Sarbeco assay using MS2 as an internal extraction control and  
489 aliquots of SARS-CoV-2/England/2/2020 as a positive control. The master mix comprised *E*- gene F  
490 and R primers and TM-P (400 nM, 400 nM and 200 nM final concentration respectively), MS2

491 primers and TM probe (20 nM, 20 nM and 40 nM final concentration respectively), 4 x TaqMan® Fast  
492 Virus 1-Step Master Mix made up with molecular-grade nuclease free water (Ambion) to a final  
493 volume of 15 µl. 5 µl of AVE buffer extract was used as a template and added to the 15 µl mastermix.  
494 Cycling conditions were 55°C for 10 min, followed by 94°C for 3 min and 45 cycles of 95°C for 15 s  
495 and 58°C for 30 s.

#### 496 *SARS-CoV-2 (2019-nCoV) CDC qPCR Probe Assay*

497 Single step RT-qPCR against the *N1* and *N2* gene targets of SARS-CoV-2 was carried out using  
498 integrated design technologies kit (IDT; Catalogue number: 10006606) according to manufacturer's  
499 instructions for use (IFU) on either a LC480 II or ABI 7500 FAST instrument. RNA extracted on Qiagen  
500 QIASymphony and the Roche FLOW system were analysed using this RT-qPCR assay.

501

#### 502 **RT-LAMP**

503 RT-LAMP assays were performed using OptiGene Ltd. (Horsham, UK) COVID-19\_RT-LAMP kits, as  
504 described previously(4), with the following modifications. The COVID-19\_RNA RT-LAMP KIT-500 kit  
505 was used for RNA RT-LAMP and the COVID-19\_Direct PLUS RT-LAMP KIT-500 was used for Direct RT-  
506 LAMP directly on oropharyngeal/nasopharyngeal swabs or saliva samples. The COVID-19\_Direct  
507 PLUS RT-LAMP KIT-500 kit also includes a sample preparation buffer, RapiLyze. For RNA RT-LAMP 5  
508 µl of extracted RNA was added to the reaction. For the Direct PLUS RT-LAMP, 50 µl sample (swab  
509 VTM or neat saliva) was added to 50 µl RapiLyze, vortexed and placed in a dry heat block pre-heated  
510 to 98°C for 2 mins. 5 µl of the treated sample was added to each reaction.

511 The anneal temperature ( $T_a$ ) that confirmed a positive result for Direct RT-LAMP was modified to  
512 81.5°C and 85.99°C because of the effect of RapiLyze buffer on the reaction.

513

514

## 515 **SARS-CoV-2 viral culture of clinical samples across a C<sub>T</sub> range**

516 For culture 100 µl and 100 µl of a 1 in 10 dilution of the first 10 samples (with predicted lower C<sub>T</sub>  
517 values) and 100 µl from the second twenty samples (with higher predicted C<sub>T</sub> values) were added to  
518 a 25 cm<sup>2</sup> flasks containing 80% confluent Vero E6 cells and allowed to adsorb for 1 hour. Five ml of  
519 Minimum Essential Medium (MEM) (Gibco) + HEPES (Gibco) + 4% foetal calf serum FCS (Sigma) + 1 x  
520 antibiotic-antimycotic (Gibco) was added to each flask and incubated for 1 week at 37°C. Two  
521 negative control flasks to which 100 µl MEM + 4% FCS was added in place of sample, were set up in  
522 parallel. Cultures were checked visually for cytopathic effect (cpe). Where cpe was not observed  
523 after 1 week, 500 µl of supernatant was passed into a fresh flask containing Vero E6 cells for a  
524 further two passages. At the beginning and end of each passage 140 µl of supernatant was collected  
525 for SARS-CoV-2 RT-qPCR as described before.

526 To determine the sensitivity of isolation method for SARS-CoV-2 from clinical samples, a virus stock  
527 titred by plaque assay (HCM/V/53), a P3 working bank grown from SARS-CoV-2 Strain England 2,  
528 from Public Health England, was diluted in MEM to give virus dilutions containing 1000 pfu to 0.01  
529 pfu. Virus isolation was performed as above in duplicate. After 72 hours of incubation flasks were  
530 checked for cpe, and for those where cpe was observed the supernatant was collected for RT-qPCR.  
531 Any flasks not showing cpe after 7 days were passed on to fresh cells and resampled as described  
532 above.

533

## 534 **Data analysis**

535 Overall diagnostic sensitivity and specificity (including 95% Clopper-Pearson confidence intervals)  
536 were calculated by the aggregation of individual site data for each method (RNA and Direct RT-  
537 LAMP) for each sample type (swabs and saliva). To demonstrate the effectiveness of detecting

538 samples with higher viral load, confusion matrices are quoted where the threshold for *positive*

539 sample inclusion varies, i.e., for  $C_T \leq 25$ , only positive samples with  $C_T \leq 25$  are included.

540 To account for site heterogeneity, a bivariate meta-analysis model is additionally applied at the site

541 level to produce a summary sensitivity and specificity for each method and sample type(12). Within-

542 study variability for sensitivity  $\rho_{se,i}$  and specificity  $\rho_{sp,i}$  are assumed to follow independent binomial

543 distributions

$$544 \quad x_{se,i} \sim B(n_{se,i}, \rho_{se,i}), \quad x_{sp,i} \sim B(n_{sp,i}, \rho_{sp,i})$$

545 where  $x_{se,i}, x_{sp,i}$  represent the number testing positive for site  $i$  respectively, and  $n_{se,i}, n_{sp,i}$

546 represent the number testing positive and negative by RT-qPCR for site  $i$  respectively. The between-

547 study heterogeneity is represented by a bivariate normal distribution for the logit-transformed

548 sensitivity  $\mu_{se,i}$  and specificity  $\mu_{sp,i}$

$$549 \quad \begin{pmatrix} \mu_{se,i} \\ \mu_{sp,i} \end{pmatrix} \sim N \left( \begin{pmatrix} \mu_{se} \\ \mu_{sp} \end{pmatrix}, \begin{pmatrix} \sigma_{se}^2 & \sigma_{se,sp} \\ \sigma_{se,sp} & \sigma_{sp}^2 \end{pmatrix} \right)$$

550 where  $\mu_{se}, \mu_{sp}$  represent the expected logit sensitivity and specificity,  $\sigma_{se}^2, \sigma_{sp}^2$  represent the

551 between-study variance in the logit sensitivity and specificity, and  $\sigma_{se,sp}$  represents the covariance

552 between the logit sensitivity and specificity. For Direct RT-LAMP, we fit a univariate normal

553 distribution for the logit-transformed sensitivity only due to the absence of false positives across all

554 sites.

555 In addition, the sensitivity as a function of viral load was assessed for RNA RT-LAMP and Direct RT-

556 LAMP on both swab and saliva samples. This was performed through the conversion of each sample

557  $C_T$  value to viral load in gene copies/ml for all sample sets. As the relationship between  $C_T$  value and

558 viral load varied according to the RT-qPCR method used; a dilution series was utilised for each

559 method to standardise these values for two of the four aforementioned RT-qPCR methods (CerTest

560 VIASURE SARS-CoV-2 real time PCR kit, and Corman *et al* RT-qPCR assay *E* gene), which was used for

561 testing 100% of the swab samples, 90% of the saliva samples used for Direct RT-LAMP, and 83% of  
562 the saliva samples used for RNA RT-LAMP. The logarithm of the viral load was then fitted to the  $C_T$   
563 values for both methods using linear regression followed by converting the  $C_T$  values to viral load  
564 based on which method had been used to evaluate the samples. For the remaining samples ( $n= 56$ )  
565 that utilised one of the other two RT-qPCR methods for which viral load was not standardised  
566 against a  $C_T$  value, the conversion derived from the CerTest VIASURE SARS-CoV-2 real time PCR kit  
567 dilution series was applied, the assumption that the *N* gene  $C_T$  values are the most similar(13–15).  
568 For the CerTest VIASURE SARS-CoV-2 real time PCR kit, the following relationship between log viral  
569 load and  $C_T$  value was applied:

570 
$$\log_{10} V = (45.257 - C_T) / 3.523$$

571 and similarly, for the Corman *et al* RT-qPCR assay:

572 
$$\log_{10} V = (45.806 - C_T) / 3.717$$

573 where  $V$  represents the viral load in copies/ml.

574 Viral load was grouped according to the following categories (in copies/ml):  $<10^3$ ,  $10^3$ - $10^4$ ,  $10^4$ - $10^5$ ,  
575  $10^5$ - $10^6$ ,  $10^6$ - $10^7$  and  $>10^7$  then the diagnostic sensitivity was calculated according to viral load group  
576 with associated Clopper-Pearson 95% confidence intervals.

577 The site meta-analysis was produced using R 3.5.3. Confusion matrices, sensitivity, specificity,  
578 sensitivity as a function of viral load calculations, and the production of scatter graphs showing the  
579 relationship between RT-LAMP results and  $C_T$  were performed using Python 3.8.6.

580

581

582

583

584 **Ethical statement**

585 We confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics  
586 committee approvals have been obtained. National Research Ethics Service Committee West  
587 Midlands - South Birmingham 2002/201 Amendment Number 4. All necessary written participant  
588 consent has been obtained and the appropriate institutional forms have been archived.

589

590 **Funding**

591 This work was partially funded by a Department of Health and Social Care award to the University of  
592 Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva  
593 315 based LAMP testing)). The views expressed are those of the authors and not necessarily those of  
594 the Department of Health and Social Care. KMG is supported by the UK Medical Research Council  
595 (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-  
596 318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the  
597 British Heart Foundation (RG/15/17/3174). For part of this project, Emma Howson was on  
598 secondment at GeneSys Biotech Ltd., which was part funded by The Pirbright Institute Flexible  
599 Talent Mobility Account (FTMA) under BBSRC grant BB/S507945/1. ADB is currently supported by a  
600 Cancer Research UK Advanced Clinician Scientist award (C31641/A23923) and his laboratory is  
601 supported by CRUK Centre Birmingham (C17422/A25154) and the Birmingham Experimental Cancer  
602 Medicine Centre (C11497/A25127). Veronica Fowler, Stephen Kidd, Bryony Armson and Zandra  
603 Deans were on secondment to the Department of Health and Social Care for a period during this  
604 study. APHA laboratory activities and expertise was supported by both the Safe and Certain project  
605 APHACSKL0085 and Defra project APHANSOM0416.

606

607 **Author contributions**

608 Conceptualization, SPK, ADB, AW, AR, MA, NM, DP, ZD, NJC, KMG, AD, SLH, VLF; Data Curation, SPK,  
609 DB, BA, ELAH, VLF; Formal Analysis SPK, DB, VLF; Investigation, SPK, BA, ADB, ELAH, AW, GS, ELW,AG,  
610 ZVM, SG, JS, CC, TL, SMR, SR, JJ, PS, AB, KD, AP, CW, JF, CB, CP,AB, MK, AR, JB, HL, SF,CT, AS, HP,  
611 NaM, SL, CW, RH, JP, JSJ, IB, DP, NJC, KMG, VLF; Methodology SPK, BA, ELAH, JS, CC, AB, IB, NJC, VLF;  
612 Writing – Original Draft Preparation SPK, DB, AW, KMG, VLF; Writing – Review & Editing, all authors  
613 contributed to critical review and editing.

614

## 615 References

- 616 1. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical  
617 characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy Eur J*  
618 *Allergy Clin Immunol.* 2020;75(7):1730–41.
- 619 2. Johns Hopkins Coronavirus Resource Centre [Internet]. [cited 2021 Apr 19]. Available from:  
620 <https://coronavirus.jhu.edu/>
- 621 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019  
622 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance.* 2020;25(3):23–30.
- 623 4. Fowler VL, Armson B, Gonzales JL, Wise EL, Howson ELA, Vincent-Mistiaen Z, et al. A highly  
624 effective reverse-transcription loop-mediated isothermal amplification (RT-LAMP) assay for  
625 the rapid detection of SARS-CoV-2 infection. *J Infect [Internet].* 2020;82(1):117–25. Available  
626 from: <https://doi.org/10.1016/j.jinf.2020.10.039>
- 627 5. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J*  
628 *Infect.* 2020;81(3):e48–50.
- 629 6. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, et al. Simply saliva: stability of  
630 SARS-CoV-2 detection negates the need for expensive collection devices. *medRxiv : the*  
631 *preprint server for health sciences.* 2020.
- 632 7. Azzi L, Baj A, Alberio T, Lualdi M, Veronesi G, Carcano G, et al. Rapid Salivary Test suitable for  
633 a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. *J Clean Prod.*  
634 2020;81.
- 635 8. Wei S, Suryawanshi H, Djandji A, Kohl E, Morgan S, Hod EA, et al. Field-deployable, rapid  
636 diagnostic testing of saliva for SARS-CoV-2 [Internet]. Vol. 11, *Scientific reports.* Columbia  
637 University Irving Medical Center, New York, NY, USA.; 2021. p. 5448. Available from:  
638 <http://europepmc.org/abstract/MED/33750853>
- 639 9. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A Review of Salivary Diagnostics and  
640 Its Potential Implication in Detection of Covid-19. *Cureus.* 2020;12(4).
- 641 10. Beaumont A, Raillon L, Ader F, Chatenoud L, Hueso T. Evaluation of different sample  
642 treatments options in a simple and safe procedure for the detection of SARS-COV-2 in saliva.  
643 2020;(January).
- 644 11. Howson ELA, Kidd SP, Armson B, Goring A, Sawyer J, Cassar C, et al. Preliminary optimisation  
645 of a simplified sample preparation method to permit direct detection of SARS-CoV-2 within  
646 saliva samples using reverse-transcription loop-mediated isothermal amplification (RT-LAMP).  
647 *J Virol Methods.* 2021;289.
- 648 12. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate  
649 analysis of sensitivity and specificity produces informative summary measures in diagnostic  
650 reviews. *J Clin Epidemiol.* 2005 Oct;58(10):982–90.
- 651 13. Bhargava A. Dynamic aspects of ORF1ab and N RNA cycle threshold values among COVID-19  
652 patients in China. *Infect Genet Evol [Internet].* 2021;87:104657. Available from:  
653 <https://www.sciencedirect.com/science/article/pii/S1567134820304883>
- 654 14. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in  
655 diagnostic samples are not an indicator of active replication. *Nat Commun [Internet].*  
656 2020;11(1):6059. Available from: <https://doi.org/10.1038/s41467-020-19883-7>
- 657 15. Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in

- 658 imported and non-imported patients with COVID-19. *Int J Infect Dis IJID Off Publ Int Soc*  
659 *Infect Dis*. 2020 May;94:68–71.
- 660 16. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial Cells Lining Salivary Gland Ducts  
661 Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the  
662 Upper Respiratory Tracts of Rhesus Macaques. *J Virol*. 2011;85(8):4025–30.
- 663 17. Huang N, Pérez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the  
664 oral cavity and saliva. *Nat Med*. 2021 Mar;
- 665 18. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load  
666 in posterior oropharyngeal saliva samples and serum antibody responses during infection by  
667 SARS-CoV-2: an observational cohort study. *Lancet Infect Dis*. 2020;20(5):565–74.
- 668 19. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-  
669 CoV-2 detection. *Lancet Respir Med [Internet]*. 2021;2600(21):19–21. Available from:  
670 <http://www.ncbi.nlm.nih.gov/pubmed/33887248>
- 671 20. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, et al. Accuracy and stability  
672 of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol*.  
673 2021;74(1):67–8.
- 674 21. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.  
675 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *The New England*  
676 *journal of medicine*. 2020.
- 677 22. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, et al. SalivaDirect: A  
678 Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity. *Med*. 2020;1–18.
- 679 23. Buck MD, Poirier EZ, Cardoso A, Frederico B, Canton J, Barrell S, et al. SARS-CoV-2 detection  
680 by a clinical diagnostic RT-LAMP assay. *Wellcome Open Res*. 2021;6:9.
- 681 24. Kellner MJ, Matl M, Ross JJ, Schnabl J, Handler D, Heinen R, et al. Head-to-head comparison  
682 of direct-input RT-PCR and RT-LAMP against RT-qPCR on extracted RNA for rapid SARS-CoV-2  
683 diagnostics. *medRxiv [Internet]*. 2021;2021.01.19.21250079. Available from:  
684 <https://doi.org/10.1101/2021.01.19.21250079>
- 685 25. Ochert AS, Boulter AW, Birnbaum W, Johnson NW, Teo CG. Inhibitory effect of salivary fluids  
686 on PCR: Potency and removal. *PCR Methods Appl*. 1994;3(6):365–8.
- 687 26. Wilson IG. Inhibition and facilitation of nucleic acid amplification. *Appl Environ Microbiol*.  
688 1997;63(10):3741–51.
- 689 27. DHSC. Rapid evaluation of OptiGene RT-LAMP assay (direct and RNA formats). Department of  
690 Health and Social Care. United Kingdom. 2020.
- 691 28. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as  
692 determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from  
693 infectious disease wards. *Eur J Clin Microbiol Infect Dis*. 2020;39(6):1059–61.
- 694 29. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe  
695 Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis*.  
696 2020;71(10):2663–6.
- 697 30. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological  
698 assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581(7809):465–9.
- 699 31. Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, et al. Quantifying

- 700 the relationship between SARS-CoV-2 viral load and infectiousness. medRxiv [Internet].  
701 2021;2021.05.07.21256341. Available from: <https://doi.org/10.1101/2021.05.07.21256341>
- 702 32. Fowler VL, Douglas A, Godfrey KM, Williams A, Beggs A, Kidd SP, et al. Critical evaluation of  
703 the methodology used by Wilson-Davies et al., (2020) entitled “Concerning the Optigene  
704 Direct LAMP assay, and it’s use in at-risk groups and hospital staff.” J Infect. 2021;
- 705 33. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, et al. Self-collected  
706 anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal  
707 swabs for the molecular detection of SARS-CoV-2. J Clin Microbiol. 2020;(July):1–5.
- 708 34. Nikolai LA, Meyer CG, Kreamsner PG, Velavan TP. Since January 2020 Elsevier has created a  
709 COVID-19 resource centre with free information in English and Mandarin on the novel  
710 coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the  
711 company ’ s public news and information . 2020;(January).
- 712 35. Marks M, Millat P, Ouchi D, Roberts C, Alemany A, Corbacho-Monné M, et al. Transmission of  
713 COVID-19 in 282 clusters in Catalonia, Spain: A cohort study. medRxiv. 2020;3099(20):1–8.
- 714 36. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of  
715 asymptomatic COVID-19 and its potential for community transmission: Systematic review and  
716 meta-analysis. J Assoc Med Microbiol Infect Dis Canada. 2020;5(4):223–34.
- 717 37. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.  
718 Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2  
719 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):1–25.
- 720 38. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is  
721 secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021;7(1):1–  
722 11.
- 723 39. Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. An observational  
724 study of SARS-CoV-2 infectivity by viral load and demographic factors and the utility lateral  
725 flow devices to prevent transmission. Preprint.
- 726 40. Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, et al. Viral dynamics of SARS-CoV-2  
727 infection and the predictive value of repeat testing. medRxiv. 2020;1–13.
- 728 41. Howson ELA, Armson B, Madi M, Kasanga CJ, Kandusi S, Sallu R, et al. Evaluation of Two  
729 Lyophilized Molecular Assays to Rapidly Detect Foot-and-Mouth Disease Virus Directly from  
730 Clinical Samples in Field Settings. Transbound Emerg Dis. 2017;64(3):861–71.
- 731 42. Armson B, Walsh C, Morant N, Fowler VL, Knowles NJ, Clark D. The development of two field-  
732 ready reverse transcription loop-mediated isothermal amplification assays for the rapid  
733 detection of Seneca Valley virus 1. Transbound Emerg Dis. 2019;66(1):497–504.
- 734 43. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. NERVTAG note on  
735 B.1.1.7 severity. 2021. p. 5–8.
- 736 44. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence  
737 and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-  
738 CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;2.
- 739 45. Public Health England. COVID-19 (SARS-CoV-2) variants [Internet]. 11/06/2021. [cited 2021  
740 Jun 17]. Available from: <https://www.gov.uk/government/collections/new-sars-cov-2-variant>
- 741 46. Vanaerschot M, Mann SA, Webber JT, Kamm J, Bell SM, Bell J, et al. Identification of a  
742 Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts Detection by Reverse

743 Transcription-PCR. Caliendo AM, editor. J Clin Microbiol [Internet]. 2020 Dec  
744 17;59(1):e02369-20. Available from: <http://jcm.asm.org/content/59/1/e02369-20.abstract>

745 47. Hasan MR, Sundararaju S, Manickam C, Mirza F, Al-Hail H, Lorenz S, et al. A Novel Point  
746 Mutation in the N Gene of SARS-CoV-2 May Affect the Detection of the Virus by Reverse  
747 Transcription-Quantitative PCR. McAdam AJ, editor. J Clin Microbiol [Internet]. 2021 Mar  
748 19;59(4):e03278-20. Available from: <http://jcm.asm.org/content/59/4/e03278-20.abstract>

749 48. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, et al. A Recurrent Mutation at  
750 Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse  
751 Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. Caliendo AM,  
752 editor. J Clin Microbiol [Internet]. 2020 Sep 22;58(10):e01598-20. Available from:  
753 <http://jcm.asm.org/content/58/10/e01598-20.abstract>

754 49. Wang R, Hozumi Y, Yin C, Wei G-W. Mutations on COVID-19 diagnostic targets. Genomics  
755 [Internet]. 2020;112(6):5204–13. Available from:  
756 <https://www.sciencedirect.com/science/article/pii/S0888754320306546>

757 50. Rausch JW, Capoferri AA, Katusiime MG, Patro SC, Kearney MF. Low genetic diversity may be  
758 an Achilles heel of SARS-CoV-2. Proc Natl Acad Sci [Internet]. 2020 Oct 6;117(40):24614 LP –  
759 24616. Available from: <http://www.pnas.org/content/117/40/24614.abstract>

760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779

780 **Supplementary Information 1**

781 **Log reduction of SARS-CoV-2 for the heat and lysis steps used independently and sequentially**

782

783 We have determined the viral inactivation kinetics of the best sample preparation condition(s),  
784 evaluating the effect of the heat and lysis steps on the viral inactivation of SARS-CoV-2 as determined  
785 by infectivity assays. All inactivation experiments had to be conducted under Containment Level 3  
786 Containment and as such was undertaken at APHA.

787 Heat inactivation experiments were conducted utilising high titre live SARS-CoV-2 virus spiked into  
788 pools of saliva collected from APHA staff or in tissue culture supernatant (TCSN). Early experiments  
789 demonstrated that saliva had a high toxicity for tissue culture cells, even after heat inactivation  
790 demonstrating that toxicity was likely not enzymatic. As such further inactivation was undertaken on  
791 live virus TCSN. These heat inactivation experiments demonstrated that SARS-Cov-2 was completely  
792 inactivated by heating at 60°C (20 min plus) or ≥70°C (after 2, 5 or 10 min). Importantly optimised  
793 RapiLyze Sample Lysis Buffer did not inactivate live virus on its own without a heat step. Further,  
794 inactivation at 56°C was not 100% effective at shorter incubation times, and additionally showed a  
795 loss in sensitivity following a 4 x 2-fold dilution (See table 2, P07102) at 10 and 30 minutes.

796

P07553 (C <sub>T</sub> 19)	1:2	1:4	1:8	1:16	1:36	1:64	1:128	1:256	1:512	1:1024	1:2048
VTM 1:1 into Lysis + 98°C	D	D	D	D	D	D	D	D	D	D	D
	D	D	D	D	D	D	D	D	D	D	D
56°C 10 mins pre-treat 1:1 VTM into lysis +98°C	D	D	D	D	D	D	D	D	D	D	ND
	D	D	D	D	D	D	D	D	D	D	ND
56°C 30 mins pre-treat 1:1 VTM into lysis +98°C	D	D	D	D	D	D	D	ND	D	ND	ND
	D	D	D	D	D	D	D	D	ND	ND	ND

797 **Table 1:** Serial dilution of Patient VTM (C<sub>T</sub> 19) 1:1 VTM into Lysis Buffer and 98°C heat treatment without and  
798 without heat pre-treatment at 56°C for 10 or 30 minutes. **D** – RNA Detected, **ND** – RNA Not Detected, by Direct  
799 RT-LAMP.

800

801

Patient VTM	P07553 (C <sub>T</sub> 19)	P01127 (C <sub>T</sub> 23.97)	P07102 (C <sub>T</sub> 32.08)	P07392 (C <sub>T</sub> 24.55)	P01071 (C <sub>T</sub> 20.54)
VTM into 1:1 Lysis + 98°C	D	D	D	D	D
	D	D	D	D	D
56°C 30 mins pre-treat 1:1 VTM into lysis + 98°C	D	D	ND	D	D
	D	D	ND	D	D

802 **Table 2:** Serial dilution of Patient VTM (C<sub>T</sub> 19.00 to 32.08) 1:1 VTM into Lysis Buffer and 98°C heat treatment  
803 without and without heat pre-treatment at 56°C for 10 or 30 minutes. **D** – RNA Detected, **ND** – RNA Not  
804 Detected, by Direct RT-LAMP.

805

806 Interestingly, following optimisation of heat inactivation of live virus, pre-treatment of samples was  
807 assessed to determine any impact of pre-treatment on assay sensitivity. A pre-treatment 70°C for 5  
808 mins carried out on spiked samples prior to the proposed direct RT-LAMP assay has no effect on  
809 subsequent LAMP or PCR results. Further experiments to test the effect of this pre-treatment on  
810 positive patient samples will be carried out to confirm this result. It recommended that even if a pre-  
811 treatment is effective in inactivating the virus that downstream processes are carried out in UV  
812 hoods or with effective air-flow management to prevent cross contamination of the direct RT-LAMP  
813 assay.

814 Comparison of Betapropiolactone (BPL) inactivated virus and live virus have demonstrated that BPL  
815 inactivation has resulted in lower sensitivity of detection using direct RT-LAMP. BPL inactivated virus  
816 is not an ideal substitute for live virus in spiking experiments. Any conclusions on assay sensitivity or  
817 performance have therefore been drawn from experiments on spiking of live virus in TCSN or saliva  
818 carried out in containment. Spiking of live virus into pooled saliva has demonstrated that direct  
819 detection by RT-LAMP is possible in samples that give a C<sub>T</sub> below 25/26 with extraction and PCR.

820

821

822 **Supplementary Information 2**

823

824 Sensitivity of the viral culture assay – 1 pfu/ml

825

826 The virus was diluted and a set number of pfu of virus (1000, 100, 10, 1 and 0.1) was added to duplicate  
827 flasks containing Vero E6 cells and also AVL. Flasks were viewed for cpe. Supernatant from flasks that  
828 showed no cpe were passed on twice. No cpe was observed in the flasks inoculated with 0.1 or 0.01  
829 pfu after the two passes. AVL samples were taken from the flasks at the beginning and end of each  
830 passage and the C<sub>T</sub> values of the extracted nucleic acids shown below.

Number of pfu added to AVL/flask	E Gene Rt-PCR assay			Growth (cpe)	
	Ct value of dilution (AVL)	Baseline Mean Ct value from flasks	Final Mean Ct value from flasks	Flask 1	Flask 2
1000	19.64	25.0	12.2	+	+
100	22.65	28.4	11.8	+	+
10	26.00	31.8	11.9	+	+
1	28.73	35.0	12.6	+	+
0.1	32.11	37.6	37.3	-	-
0.01	34.43	39.8	37.7	-	-

831

832

833

834

835

836

837

838

839

840

841

842

843

844 **Supplementary Information 3**

845

846

847 **Table 5.** RT-LAMP results of time course from symptom onset

Days post suspected exposure	Direct RT-LAMP			RNA RT-LAMP			RT-qPCR C <sub>T</sub>		Observed Symptoms
	Tp 1	Tp 2	Result	Tp 1	Tp 2	Result	ORF1ab	N	
5	09:18	09:32	POS	11:09	10:50	POS	23.31	26.47	Onset: Sore throat. Blocked nose. Headache. Lack of appetite. Fever.
6	10:32	11:34	POS	10:34	10:40	POS	21.16	24.03	Sore throat. Headache. Restless sleeping. Tired
7	10:19	13:40	POS	11:39	09:59	POS	24.47	27.30	Headache. Restless sleeping. Tired. Loss of smell and taste.
9	09:31	09:14	POS	08:35	09:37	POS	28.55	31.89	Tired. Loss of smell and taste.
11	13:14	11:47	POS	16:44	16:39	POS	26.44	29.06	Tired. Loss of smell and taste.
12	09:10	10:09	POS	12:42	12:01	POS	26.13	29.19	Tired. Improvement in smell and taste.
13	NEG	NEG	NEG	14:06	12:56	POS	28.16	30.62	Significant improvement in all symptoms
14	NEG	NEG	NEG	NEG	NEG	NEG	38.05	40.73	None
16	NEG	NEG	NEG	NEG	NEG	NEG	36.11	NEG	None
17	NEG	NEG	NEG	NEG	NEG	NEG	NEG	NEG	None

848 Time to positivity in minutes [Tp]; Cycle Threshold [C<sub>T</sub>]; Negative [NEG]; positive [POS]

849

850

851